Empirical progression criteria thresholds for feasibility outcomes in HIV clinical trials: a methodological study

Pilot and Feasibility Studies

Methodology

Maya Stevens-Uninsky¹  Nadia Rehman²  Amidu Raifu²  Lawrence Mbuagbaw³  Lucy Huizhu Chen⁴  Eunice Aluko⁵  Tariq Atkin-Jones⁶  Akudo C. J. Eze-Onuorah⁶  Larysa Stech⁷  Michael Cristian Garcia⁸ 

[1] Department of Global Health, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada;Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main Street West, L8S4L8, Hamilton, ON, Canada;Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main Street West, L8S4L8, Hamilton, ON, Canada;Centre for Development of Best Practices in Health (CDBPH), Yaoundé Central Hospital, Yaoundé, Cameroon;Department of Medicine, McMaster University, Hamilton, ON, Canada;Department of Anesthesia, McMaster University, Hamilton, ON, Canada;Department of Pediatrics, McMaster University, Hamilton, ON, Canada;Biostatistics Unit, Father Sean O’Sullivan Research Centre, St Joseph’s Healthcare Hamilton, Hamilton, ON, Canada;Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Cape Town, South Africa;Department of Medicine, McMaster University, Hamilton, ON, Canada;Faculty of Arts and Science, University of Toronto, Toronto, ON, Canada;Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada;Public Health, Faculty of Applied Sciences, Brock University, St. Catharines, ON, Canada;Temerty Faculty of Medicine, University of Toronto, Toronto, Canada;

关键词: HIV;    Pilot trial;    Feasibility trial;    Progression criteria;    Threshold;    Clinical trials;   

DOI  :  10.1186/s40814-023-01342-x

 received in 2023-01-10, accepted in 2023-06-07,  发布年份 2023

来源: Springer

【 摘 要 】

IntroductionPilot and feasibility trials use predetermined thresholds for feasibility outcomes to decide if a larger trial is feasible. These thresholds may be derived from the literature, observational data, or clinical experience. The aim of this study was to determine empirical estimates for feasibility outcomes to inform future HIV pilot randomized trials.MethodsWe conducted a methodological study of HIV clinical trials indexed in the past 5 years (2017–2021) in the PubMed database. We included trials of people living with HIV individually randomized to any type of intervention and excluded pilot trials and cluster randomized trials. Screening and data extraction were conducted in duplicate. We computed estimates for recruitment, randomization, non-compliance, lost to follow-up, discontinuation, and the proportion analyzed using a random effects meta-analysis of proportions and reported these estimates according to the following subgroups: use of medication, intervention type, trial design, income level, WHO region, participant type, comorbidities, and source of funding. We report estimates with 95% confidence intervals.ResultsWe identified 2122 studies in our search, of which 701 full texts were deemed relevant, but only 394 met our inclusion criteria. We found the following estimates: recruitment (64.1%; 95% CI 57.7 to 70.3; 156 trials); randomization (97.1%; 95% CI 95.8 to 98.3; 187 trials); non-compliance (3.8%; 95% CI 2.8 to 4.9; 216 trials); lost to follow-up (5.8%; 95% CI 4.9 to 6.8; 251 trials); discontinuation (6.5%; 95% CI 5.5 to 7.5; 215 trials); analyzed (94.2%; 95% CI 92.9 to 95.3; 367 trials). There were differences in estimates across most subgroups.ConclusionThese estimates may be used to inform the design of HIV pilot randomized trials with careful consideration of variations due to some of the subgroups investigated.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 4